| Literature DB >> 33860614 |
Claudio Babiloni1,2, Xianghong Arakaki3, Hamed Azami4, Karim Bennys5, Katarzyna Blinowska6,7, Laura Bonanni8, Ana Bujan9, Maria C Carrillo10, Andrzej Cichocki11,12,13, Jaisalmer de Frutos-Lucas14, Claudio Del Percio1, Bruno Dubois15,16, Rebecca Edelmayer10, Gary Egan17, Stephane Epelbaum15,16, Javier Escudero18, Alan Evans19, Francesca Farina20, Keith Fargo10, Alberto Fernández14, Raffaele Ferri21, Giovanni Frisoni22,23, Harald Hampel24, Michael G Harrington3, Vesna Jelic25, Jaeseung Jeong26, Yang Jiang27, Maciej Kaminski7, Voyko Kavcic28, Kerry Kilborn29, Sanjeev Kumar30, Alice Lam31, Lew Lim32, Roberta Lizio33, David Lopez14, Susanna Lopez1, Brendan Lucey34, Fernando Maestú14, William J McGeown35, Ian McKeith36, Davide Vito Moretti22, Flavio Nobili37,38, Giuseppe Noce33, John Olichney39, Marco Onofrj8, Ricardo Osorio40, Mario Parra-Rodriguez35, Tarek Rajji30, Petra Ritter41,42, Andrea Soricelli33,43, Fabrizio Stocchi44, Ioannis Tarnanas45,46, John Paul Taylor36, Stefan Teipel47,48, Federico Tucci1, Mitchell Valdes-Sosa49, Pedro Valdes-Sosa49,50, Marco Weiergräber51, Gorsev Yener52, Bahar Guntekin53,54.
Abstract
The Electrophysiology Professional Interest Area (EPIA) and Global Brain Consortium endorsed recommendations on candidate electroencephalography (EEG) measures for Alzheimer's disease (AD) clinical trials. The Panel reviewed the field literature. As most consistent findings, AD patients with mild cognitive impairment and dementia showed abnormalities in peak frequency, power, and "interrelatedness" at posterior alpha (8-12 Hz) and widespread delta (< 4 Hz) and theta (4-8 Hz) rhythms in relation to disease progression and interventions. The following consensus statements were subscribed: (1) Standardization of instructions to patients, resting state EEG (rsEEG) recording methods, and selection of artifact-free rsEEG periods are needed; (2) power density and "interrelatedness" rsEEG measures (e.g., directed transfer function, phase lag index, linear lagged connectivity, etc.) at delta, theta, and alpha frequency bands may be use for stratification of AD patients and monitoring of disease progression and intervention; and (3) international multisectoral initiatives are mandatory for regulatory purposes.Entities:
Keywords: Alzheimer's disease; The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART); biomarkers; clinical trials; dementia; electroencephalography (EEG); eyes-closed resting state condition
Mesh：
Year: 2021 PMID： 33860614 PMCID： PMC8647863 DOI： 10.1002/alz.12311
Source DB: PubMed Journal: Alzheimers Dement ISSN： 1552-5260 Impact factor: 16.655